TechCrunch AI · 2026/10/21 04:35:10
OpenAI 收购 Orchestra Bio 强化生物计算布局
OpenAI 宣布收购成立四年的 AI 生物科技初创公司 Orchestra Bio，旨在增强其生命科学领域的竞争力。Orchestra 团队与技术将被整合进 OpenAI 的 Rosalind 模型及 Workbench 工具中，以优化药物发现流程管理。此举标志着大模型厂商正加速通过并购垂直领域初创企业来构建行业专用软件生态。
报道全文原始报道全文
Image Credits:FotografiaBasica (opens in a new window) / Getty Images
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.